Topical Rapamycin (Anti-Aging)
mTOR inhibitor for cellular-level anti-aging via topical application
About This Treatment
Rapamycin (Sirolimus) inhibits the mTOR pathway, a central regulator of cellular aging. Originally an immunosuppressant, topical rapamycin is now emerging as a revolutionary anti-aging treatment.
Clinical trials showed photoaging improvement (fine wrinkle reduction, dermal volume increase, even skin tone). Histology confirmed decreased p16INK4A (aging marker) and increased Collagen VII. Addresses root aging mechanisms unlike conventional retinoids.
Mechanism of Action
mTOR is a serine/threonine kinase and master regulator of cell growth, proliferation, and senescence. Rapamycin selectively inhibits mTORC1, reducing p16INK4A expression and suppressing cellular senescence. Simultaneously activates autophagy and promotes Collagen VII production, restoring basement membrane integrity.
Indications
Expected Results
Clinical trial showed visible photoaging improvement in 11 of 13 subjects. Fine wrinkle reduction, dermal volume increase, reduced vein/tendon prominence (volume loss marker). 8-12 weeks continuous use needed for results.
Clinical Evidence
Risks & Side Effects
Caution: Long-term topical safety data limited. Potential systemic immunosuppression (low risk with topical). Blood glucose elevation risk. Possible increased infection susceptibility. Skin irritation/dryness. Contraindicated in pregnancy. Use under physician supervision recommended.
Interested in this treatment?
Start with an AI skin analysis to check your current skin condition